 WORCESTER, Mass., Nov. 04, 2020 GLOBE NEWSWIRE -- Mustang Bio, Inc. Mustang NASDAQ: MBIO, a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 12 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma NHL, have been selected for a poster presentation at the 62nd American Society of Hematology ASH Annual Meeting, which is being held virtually from December 5 8, 2020. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center Fred Hutch. 